Pfizer Buys Cancer-Drug Maker Seagen for $43 Billion

Pfizer's CEO discusses the $43 billion acquisition of CGN, highlighting its potential to revolutionize cancer treatment using ADC technology. The acquisition is seen as a strategic move to leverage Pfizer's global scale and rapid clinical trial capabilities, enhancing CGN's unique technology. The CEO emphasizes the synergy between Pfizer's resources and CGN's innovations, suggesting that the combined entity will be more valuable than the sum of its parts.

Why is the timing of the engagement with the other company considered right?

What is the significance of the phrase '1 + 1 will not make it 2' in the context of the acquisition?